These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 27799249)

  • 21. Concomitant NAFLD Facilitates Liver Metastases and PD-1-Refractory by Recruiting MDSCs via CXCL5/CXCR2 in Colorectal Cancer.
    Yang Y; Chen Y; Liu Z; Chang Z; Sun Z; Zhao L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101351. PubMed ID: 38724007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
    Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
    Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression.
    Groth C; Arpinati L; Shaul ME; Winkler N; Diester K; Gengenbacher N; Weber R; Arkhypov I; Lasser S; Petrova V; Augustin HG; Altevogt P; Utikal J; Fridlender ZG; Umansky V
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells.
    Nagatani Y; Funakoshi Y; Suto H; Imamura Y; Toyoda M; Kiyota N; Yamashita K; Minami H
    J Cancer Res Ther; 2021; 17(4):1093-1100. PubMed ID: 34528569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.
    Kumar V; Donthireddy L; Marvel D; Condamine T; Wang F; Lavilla-Alonso S; Hashimoto A; Vonteddu P; Behera R; Goins MA; Mulligan C; Nam B; Hockstein N; Denstman F; Shakamuri S; Speicher DW; Weeraratna AT; Chao T; Vonderheide RH; Languino LR; Ordentlich P; Liu Q; Xu X; Lo A; Puré E; Zhang C; Loboda A; Sepulveda MA; Snyder LA; Gabrilovich DI
    Cancer Cell; 2017 Nov; 32(5):654-668.e5. PubMed ID: 29136508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of PFKFB3 on inflammatory activation of polymorphonuclear myeloid-derived suppressor cell in acute myocardial infarction].
    Yu Z; Wu Y; Liu D
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 Jan; 36(1):44-49. PubMed ID: 38404271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis.
    Nouailles G; Dorhoi A; Koch M; Zerrahn J; Weiner J; Faé KC; Arrey F; Kuhlmann S; Bandermann S; Loewe D; Mollenkopf HJ; Vogelzang A; Meyer-Schwesinger C; Mittrücker HW; McEwen G; Kaufmann SH
    J Clin Invest; 2014 Mar; 124(3):1268-82. PubMed ID: 24509076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
    Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
    Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
    Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
    Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
    Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
    Chao T; Furth EE; Vonderheide RH
    Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of endostatin gene therapy on myeloid-derived suppressor cells from a metastatic renal cell carcinoma.
    Chaves KC; Costa EM; Teixeira LF; Bellini MH
    Exp Oncol; 2018 Mar; 40(1):24-32. PubMed ID: 29600976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD205
    Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
    Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
    Rodriguez PC; Ernstoff MS; Hernandez C; Atkins M; Zabaleta J; Sierra R; Ochoa AC
    Cancer Res; 2009 Feb; 69(4):1553-60. PubMed ID: 19201693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCL5, the upregulated chemokine in patients with uterine cervix cancer, in vivo and in vitro contributes to oncogenic potential of Hela uterine cervix cancer cells.
    Feng X; Zhang D; Li X; Ma S; Zhang C; Wang J; Li Y; Liang L; Zhang P; Qu Y; Zhang Z; Yang Z; Xiang Y; Zhang W; Wang S; Shao W; Wang W
    Biomed Pharmacother; 2018 Nov; 107():1496-1504. PubMed ID: 30257367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3.
    Han X; Shi H; Sun Y; Shang C; Luan T; Wang D; Ba X; Zeng X
    Cell Death Dis; 2019 Aug; 10(8):598. PubMed ID: 31395859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
    Cui D; Zhao Y; Xu J
    Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.